IntroductionYiqi Jiedu Huayu decoction (YJHD) is a traditional Chinese medicine preparation consisting of seven herbs, which has been widely used in the treatment of diabetic cardiomyopathy (DCM) and has achieved positive treatment effects. However, due to its multicomponent, multitarget characteristics, the pharmacological mechanism of YJHD in the treatment of DCM remains unclear. MethodsThe potential mechanism of YJHD in the treatment of DCM was explored and validated using network pharmacology, molecular docking technology, and animal experiments. Compounds and targets of YJHD were obtained by the TCMSP, ETCM, and SymMap databases. Next, the targets of DCM were predicted by GeneCards and DisGeNET databases. Then, through a series of screens, the major targets of YJHD for the treatment of DCM were identified. Through GO and KEGG enrichment analysis and signaling pathway mapping, the role of major targets in the treatment of DCM was analyzed. Finally, the results were validated by molecular docking and animal experiments. Results95 active ingredients and 38 major targets were identified. Enrichment analysis indicated that YJHD may directly or indirectly regulate multiple pathways, improving myocardial glucose metabolism, inflammation, and fibrosis. The binding of active ingredients to key targets was simulated by molecular docking. In addition, animal models of DCM were established and treated with YJHD, which showed that YJHD can effectively improve the pathological changes of DCM. Furthermore, the regulatory effect of YJHD on certain key pathways were confirmed by western blotting. ConclusionThrough multicomponent and multitarget analysis, this study reveals the potential mechanisms of YJHD in DCM treatment.
Read full abstract